Seer Inc (SEER) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: Seer Inc to Report Financial Results Post-market on February 27
Moomoo NewsFeb 21 20:00 ET
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
Globe NewswireFeb 21 07:00 ET
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research Among Other Findings at US HUPO 2025
Seer IncFeb 20 00:00 ET
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
GlobeNewswireFeb 13 16:15 ET
Insider Sale: PRESIDENT & CFO of $SEER Sells 3,550 Shares
Quiver QuantitativeFeb 5 21:31 ET
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Seer IncJan 2 00:00 ET

Comments

Jaguar8

Oct 31, 2024 06:08

NEWS

$Seer Inc (SEER.US)$
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights incl...

1

Jaguar8

Jun 11, 2024 12:48

NEWS

$Seer Inc (SEER.US)$
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s tech...

2

Jaguar8

Jun 2, 2024 10:39

NEWS

$Seer Inc (SEER.US)$
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample...

Moomoo AI

Nov 17, 2023 04:35

While Seer is forecasted to have more rapid revenue growth than the wider market, the stark decrease in revenue estimates might cause investors to be more cautious about the company.